Atrial Fibrillation Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Thryv Therapeutics, AbbVie

Atrial Fibrillation Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Thryv Therapeutics, AbbVie
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Atrial Fibrillation pipeline constitutes 15+ key companies continuously working towards developing 15+ Atrial Fibrillation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Atrial Fibrillation Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market.


Some of the key takeaways from the Atrial Fibrillation Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years. 
  • Atrial Fibrillation companies working in the treatment market are Thryv Therapeutics Inc., AbbVie, Bayer AG, InCarda Therapeutics, Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, and others, are developing therapies for the Atrial Fibrillation treatment 
  • Emerging Atrial Fibrillation therapies in the different phases of clinical trials are- Research programme, AGN-151607, Asundexian, Inrhythm, CTP-Amio, VE 1902, HBI-3000, HSY 244, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.   
  • In August 2023, Bristol Myers Squibb (NYSE: BMY) announced that research will be presented at the ESC Congress, which will be held in person and digitally from August 25–28, 2023, to support the strength of its broad range of cardiovascular products. The presentation of CAMZYOS® (mavacamten) cumulative analysis up to 120-weeks and the impact of standard of care (SOC) medication from the EXPLORER cohort of the MAVA-long-term extension (LTE) study, as well as a late-breaking presentation of VALOR-HCM-LTE 56-week data, as well as fresh information from health economics outcomes research, are among the clinical studies whose data will be highlighted.
  • In December 2022, In order to compare the efficacy and safety of the oral FXIa inhibitor Asundexian (BAY 2433334) wit  h apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 and older with atrial fibrillation at risk for stroke (OCEANIC-AF), Bayer initiated a multicenter, international, randomised, active comparator-controlled, double-blind, parallel-group, 2-arm, Phase 3 study.


Atrial Fibrillation Overview

Atrial Fibrillation (AF) is an irregular or trembling heartbeat that raises the risk of blood clots, stroke, heart failure, and other issues related to the heart. The two upper chambers of the heart, known as the atria, beat erratically and chaotically during atrial fibrillation, not in time with the lower chambers, known as the ventricles.


Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Therapeutic Assessment-


Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:

  • Research programme: Thryv Therapeutics Inc.
  • AGN-151607: AbbVie
  • Asundexian: Bayer AG
  • Inrhythm: InCarda Therapeutics, Inc.
  • CTP-Amio: Vivasc Therapeutics
  • VE 1902: Verseon
  • HBI-3000: HUYA Bioscience
  • HSY 244: Novartis


Atrial Fibrillation Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular


Atrial Fibrillation Molecule Type

Atrial Fibrillation Products have been categorized under various Molecule types, such as

  • Monoclonal antibody
  • Small molecule
  • Peptide


Atrial Fibrillation Pipeline Therapeutics Assessment

  • Atrial Fibrillation Assessment by Product Type
  • Atrial Fibrillation By Stage and Product Type
  • Atrial Fibrillation Assessment by Route of Administration
  • Atrial Fibrillation By Stage and Route of Administration
  • Atrial Fibrillation Assessment by Molecule Type
  • Atrial Fibrillation by Stage and Molecule Type


DelveInsight’s Atrial Fibrillation Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies


Some of the key companies in the Atrial Fibrillation Therapeutics Market include:

Key companies developing therapies for Atrial Fibrillation are –


Atrial Fibrillation Pipeline Analysis:

The Atrial Fibrillation pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
  • Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies


Atrial Fibrillation Pipeline Market Drivers

  • Rising prevalence of Atrial fibrillation, increase in the Adoption of Advanced Technologies are some of the important factors that are fueling the Atrial Fibrillation Market.


Atrial Fibrillation Pipeline Market Barriers

  • However, complications associated with the use of Atrial fibrillation drugs, lack of awareness regarding medical therapy in underdeveloped and developing regions and other factors are creating obstacles in the Atrial Fibrillation Market growth.


Scope of Atrial Fibrillation Pipeline Drug Insight    

  • Coverage: Global
  • Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., AbbVie, Bayer AG, InCarda Therapeutics, Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, and others
  • Key Atrial Fibrillation Therapies: Research programme, AGN-151607, Asundexian, Inrhythm, CTP-Amio, VE 1902, HBI-3000, HSY 244, and others
  • Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
  • Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers 


Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials


Table of Contents 

1. Atrial Fibrillation Report Introduction

2. Atrial Fibrillation Executive Summary

3. Atrial Fibrillation Overview

4. Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment

5. Atrial Fibrillation Pipeline Therapeutics

6. Atrial Fibrillation Late Stage Products (Phase II/III)

7. Atrial Fibrillation Mid Stage Products (Phase II)

8. Atrial Fibrillation Early Stage Products (Phase I)

9. Atrial Fibrillation Preclinical Stage Products

10. Atrial Fibrillation Therapeutics Assessment

11. Atrial Fibrillation Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Atrial Fibrillation Key Companies

14. Atrial Fibrillation Key Products

15. Atrial Fibrillation Unmet Needs

16 . Atrial Fibrillation Market Drivers and Barriers

17. Atrial Fibrillation Future Perspectives and Conclusion

18. Atrial Fibrillation Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States